Suche starten De menü de ClientConnect
Suche starten
Ergebnisse
Top-5-Suchergebnisse Alle Ergebnisse anzeigen Erweiterte Suche
Häufigste Suchbegriffe
Meistbesuchte Seiten
    Referenz: 20190824
    Veröffentlichungsdatum: 9 Februar 2023

    Projektträger – zwischengeschaltetes Finanzinstitut

    DEEPULL DIAGNOSTICS SL

    Ort

    Beschreibung

    The loan will enable the promoter to increase its research, development and innovation (RDI) activities for its highly innovative easy-to-use diagnostics platform to accelerate and improve accuracy in acute infections and sepsis diagnosis. The project is financed under the Infectious Diseases Finance Facility (IDFF) set up as part of Horizon 2020, the European Union's research and innovation programme for 2014-2020.

    Additionality and Impact

    The project addresses the failure in financial markets for small innovative and high-growth companies arising from the limited access and/or prohibitive cost of financing charged by creditors/investors as a result from information asymmetries, higher uncertainty, lack of collateral and imperfect screening and monitoring. The project is in line with the objectives of Horizon Europe program. The project will deliver a testing platform for sepsis based on PCR which has a broad application in diagnostic of sepsis and antimicrobial resistance (AMR). EIB's financing would be complementary to European VC investors and would provide a signalling effect to crowd-in other capital providers, which are necessary for the completion of the product development stage and commencing commercial operations.  EIB provides long term Venture Debt financing, with longer availability and maturity than the Company would otherwise be able to raise from the markets.

    Ziele

    The related RDI activities aim to fight sepsis and antimicrobial resistance, through a faster and automated diagnostics system, based on a culture-free/label-free comprehensive microbial identification. In detail, a faster pathogen identification and antimicrobial susceptibility testing (AST), combined with an early warning classifier system, will allow making diagnosis faster and more accurate, thus helping to reduce mortality and morbidity related to sepsis and antimicrobial resistance.

    Sektor(en)

    • Industrie - Verarbeitendes Gewerbe/Herstellung von Waren

    Vorgeschlagene EIB-Finanzierung (voraussichtlicher Betrag)

    EUR 20 million

    Gesamtkosten (voraussichtlicher Betrag)

    EUR 55 million

    Umweltaspekte

    The RDI activities are expected to be carried out in existing facilities that are already used for the same purposes and that are not expected to change their scope due to the project. An environmental impact assessment (EIA) is therefore not needed as per EIA Directive 2014/52/EU amending Directive 2011/92/EU. The full environmental details will however be investigated by the Bank's services during the project due diligence.

    Auftragsvergabe

    The Promoter has been assessed by the EIB as being a private company not subject to EU rules on public procurement or concessions. However, if at the project appraisal, the EIB were to conclude that the Promoter is subject to EU public procurement legislation then the Bank would duly inform the Commission Services and would require the Promoter to apply those rules.

    Projektstatus

    Unterzeichnet - 5/12/2022

    Milestone
    In Prüfung
    Genehmigt
    Unterzeichnet
    17 August 2022
    5 Dezember 2022

    Haftungsausschluss

    Bis Finanzierungen vom Verwaltungsrat genehmigt und anschließend unterzeichnet werden, befinden sich die Projekte in der Prüfungs- oder Verhandlungsphase. Die Angaben auf dieser Seite sind daher unverbindlich.
    Sie dienen lediglich der Transparenz und stellen nicht die offizielle EIB-Politik dar (vgl. auch die erklärenden Anmerkungen).

    Tags

    Spanien Industrie